Phase III data shows faster-acting insulin aspart reduces HbA1c in type 1 diabetes versus NovoRapid (insulin aspart) - Novo Nordisk

New phase IIIa findings showed that faster-acting insulin aspart, from Novo Nordisk, demonstrated a statistically significant reduction in HbA1c in type 1 diabetes, compared with NovoRapid (insulin aspart), a comparable HbA1c reduction in type 2 diabetes versus NovoRapid and improved post-meal or postprandial glucose (PPG) control in type 1 and type 2 diabetes. In onset 1, after 26 weeks of randomized therapy, faster-acting insulin aspart showed statistically significantly greater HbA1c reduction versus NovoRapid in adults with type 1 diabetes when dosed at mealtime. Faster-acting insulin aspart also showed comparable HbA1c reduction when dosed 20 minutes after starting a meal, compared with NovoRapid dosed at mealtime.

Trial results for onset 1 also showed superior reduction in two-hour PPG increment -0.67 mmol/L) versus NovoRapid. The change in one-hour PPG increment, a secondary supportive endpoint, was also reduced (-1.18 mmol/L). In onset 2, faster-acting insulin aspart demonstrated non-inferiority in HbA1c reduction compared with NovoRapid in adults with type 2 diabetes. Trial results could not confirm a statistically significant reduction in two-hour PPG increment ( -0.36 mmol/L). However, a statistically significant reduction in one-hour PPG increment was shown with faster-acting insulin aspart (-0.59 mmol/L) which was a secondary supportive endpoint. Results from the onset 1 and onset 2 treat-to-target trials comparing faster-acting insulin aspart with NovoRapid were presented at the 76th annual Scientific Sessions of the American Diabetes Association.